12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Promacta/Revolade eltrombopag regulatory update

GlaxoSmithKline submitted an sNDA to FDA and a variation to an MAA to EMA for Promacta/Revolade eltrombopag to treat thrombocytopenia in adults with chronic...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >